Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT03093831 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped Study did not meet the objectives and terminated early on 17 Jul 2020 due to poor recruitment

Conditions

Interventions

Sponsor

National Cancer Centre, Singapore

Collaborators